

REMARKS

As an initial matter, applicants thank the Examiner for taking the time to explain the objections to the Sequence Listing on June 14, 2007. As discussed, the Examiner agreed with the applicants that the computer-readable form of the Sequence Listing complied with the requirements under 37 CFR §1.821 - §1.825, and a substitute sequence listing in both computer readable form and paper copy is not required to be fully responsive.

The Examiner has objected to the description of Figures 7-12 contained in the specification of the instant application. Applicants have amended the Brief Description of the Drawings section of the instant specification by adding sequence identifiers to overcome the Examiner's objection. These amendments find support throughout the instant specification. Specifically, Figure 7 is described as being the nucleotide sequence of Seq. ID No.:5 in Example 2 of the instant specification. Example 2 also describes Figure 8 as setting forth the nucleotide sequence of Seq. ID No.:6. Figures 9-12 are described in Example 5 of the instant specification. The amendments to the specification were made to indicate that the sequences disclosed in Figures 7-12 were assigned SEQ ID Nos. in the previously submitted sequence listing. Accordingly, no new matter has been introduced by these amendments.

Applicants respectfully assert that the Examiner's objection to the specification is rendered moot as a result of the foregoing amendments.

Upon review of the instant application while preparing this response, applicants noticed a typographical error in the sequence of Figure 8 of the instant application. As stated in the instant specification, Figure 8 is a figure showing the sequence of primer 2 (see page 7 of the instant specification). The sequence listing provided in the instant specification shows the sequence of primer 2 as SEQ ID No.:6. However, there is a discrepancy in Figure 8 and SEQ ID No.:6. Applicants submit this amendment to Figure 8 in order to harmonize the sequence of this figure with the sequence listing that has been provided in the instant application. The amended Figure 8 is contained in the Appendix of this paper, following page 5. Applicants respectfully request consideration of this amendment.

CONCLUSION

Based on the foregoing amendments and remarks, applicants respectfully request consideration of the amended Figures 7-12 and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. Applicants respectfully request consideration of amended Figure 8.

AUTHORIZATION


The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **13-4500**, Order No. 4439-4024.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. **13-4500**, Order No. 4439-4024.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated:June 29, 2007

By:



Sonja Keehan
Reg. No. 56,390

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700
(212) 415-8701

Telephone
Facsimile